Phospho-NFKBIE (S22) Antibody

What is NFKBIE and why is its phosphorylation at S22 significant?

NFKBIE (also known as IκB-epsilon) belongs to the NF-κB inhibitor family that regulates the NF-κB signaling pathway. NFKBIE inhibits NF-κB by complexing with and trapping it in the cytoplasm, specifically inhibiting DNA-binding of NF-κB p50-p65 and p50-c-Rel complexes .

Phosphorylation at serine 22 (S22) is particularly significant because:

• It marks NFKBIE for destruction via the ubiquitination pathway

• This phosphorylation event is required for subsequent degradation that ultimately allows activation of the NF-κB complex

• The activated NF-κB complex can then translocate into the nucleus and bind to DNA at specific kappa-B-binding motifs (5'-GGGRNNYYCC-3' or 5'-HGGARNYYCC-3')

Methodologically, researchers studying NF-κB pathway activation often monitor S22 phosphorylation as a direct indicator of pathway stimulation by proinflammatory signals.

How does NFKBIE differ from other NF-κB inhibitors in structure and function?

NFKBIE differs from other NF-κB inhibitors like NFKBIA and NFKBIB in several crucial aspects:

• Expression pattern: NFKBIE shows distinct tissue distribution compared to other family members, with notable overexpression in several cancer types including hepatocellular carcinoma (HCC)

• Prognostic significance: While NFKBIA, NFKBID, and NFKBIZ show no significant effect on prognosis in certain cancers, NFKBIE expression correlates with prognosis in HCC. Specifically, patients with low NFKBIE expression have been associated with better prognosis in HCC

• Protein interactions: NFKBIE has particularly strong protein interactions with RELA, REL, CHUK, IKBKG, IKBKB, and RELB as demonstrated through protein-protein interaction network analysis

• Pathway suppression profile: NFKBIE notably suppresses multiple signaling cascades including the PI3K/AKT, RAS/MAPK, RTK, and TSC/mTOR pathways, providing a distinct regulatory profile

What are the validated applications for Phospho-NFKBIE (S22) antibodies and their optimal working dilutions?

Phospho-NFKBIE (S22) antibodies have been validated for multiple experimental applications. Based on technical validation from multiple manufacturers, the following applications and recommended working dilutions have been established:

When optimizing these protocols, researchers should:

• Include appropriate positive controls (e.g., cell lysates from TNF-α treated cells, 20ng/ml for 15-30 minutes)

• Include negative controls using blocking peptides specific to the phosphorylated epitope

• Validate specificity by comparing phosphorylated versus non-phosphorylated samples

How can researchers effectively validate the specificity of Phospho-NFKBIE (S22) antibody detection?

Ensuring antibody specificity is crucial for reliable research outcomes. Methodological approaches include:

• Phosphorylation-specific validation: Compare results using:

  • Paired antibody tests with phospho-specific and total NFKBIE antibodies

  • Treatment with phosphatase to eliminate specific signal

  • Treatment with kinase inhibitors to prevent phosphorylation

• Stimulation-dependent detection: Evaluate phosphorylation following established stimuli:

  • TNF-α treatment (20ng/ml, 15-30 minutes) in appropriate cell lines

  • Compare untreated versus treated samples in Western blot

• Blocking peptide competition: Perform parallel experiments with:

  • Antibody alone

  • Antibody pre-incubated with phospho-peptide immunogen

  • Antibody pre-incubated with non-phosphorylated peptide

  A genuine phospho-specific signal should be blocked only by the phosphorylated peptide

• Genetic validation: Use NFKBIE-knockout or knockdown models to confirm signal absence

Multiple manufacturers have demonstrated appropriate antibody specificity using these approaches, as evidenced by Western blot and immunohistochemistry validation images showing signal abolishment with blocking peptides .

What role does NFKBIE play in cancer pathogenesis, particularly hepatocellular carcinoma?

NFKBIE has emerged as a significant factor in hepatocellular carcinoma (HCC) with several key research findings:

• Differential expression: NFKBIE is overexpressed in HCC compared to normal liver tissue, making it unique among NF-κB inhibitors

• Prognostic indicator: NFKBIE expression correlates with clinical characteristics including:

  • Tumor grade

  • Tumor protein P53 mutation status

  • Tumor stage

  • Patient survival outcomes

• Pathway interactions: Research demonstrates that NFKBIE:

  • Suppresses the PI3K/AKT, RAS/MAPK, RTK and TSC/mTOR pathways

  • Shows positive correlation with the NF-κB signaling pathway

  • Is associated with primary immunodeficiency

• Functional impact: Experimental knockdown of NFKBIE has been shown to:

  • Significantly decrease both proliferation and migration of HCC cells

  • Affect "antigen processing and presentation" and "hepatocellular carcinoma" pathways

  • Impact genes involved in the p53 pathway and longevity-regulating pathway

These findings suggest NFKBIE may serve as both a prognostic biomarker and potential therapeutic target in HCC.

How is NFKBIE involved in immune cell infiltration and inflammatory responses?

NFKBIE demonstrates significant relationships with immune cell infiltration in the tumor microenvironment:

• Cell-specific associations: Research has revealed that NFKBIE expression:

  • Is higher in B cells and lower in T cells

  • Correlates negatively with endothelial cells and hematopoietic stem cells

  • Correlates positively with B cells, M1 macrophages, and myeloid dendritic cells

• Prognostic immune signatures: Studies have found that:

  • Low levels of NFKBIE combined with high T cell CD4+ effector memory, macrophages, and common lymphoid progenitors indicate a good prognosis

  • TP53 mutant samples show higher levels of B-cell infiltration than wild-type TP53 samples

• Inflammatory pathway modulation: NFKBIE functions at the intersection of inflammation and cancer:

  • Most HCC occurs in an inflamed liver, making this relationship particularly relevant

  • After NFKBIE knockdown, "antigen processing and presentation" pathways are significantly affected

  • Genes with reduced expression after NFKBIE knockdown are enriched in non-alcoholic liver disease, which can progress to liver cancer

This immune-regulatory role positions NFKBIE as a potential immunotherapeutic target, particularly for conditions with chronic inflammation.

What are the most effective experimental designs to study dynamic NFKBIE phosphorylation in cellular signaling?

To effectively study dynamic NFKBIE phosphorylation in cellular contexts, researchers should consider these methodological approaches:

• Time-course stimulation experiments:

  • Treat cells with relevant stimuli (TNF-α, IL-1β) at multiple timepoints (5, 15, 30, 60 minutes)

  • Process samples simultaneously to minimize technical variation

  • Quantify phospho-NFKBIE:total NFKBIE ratios by Western blot

• Phosphorylation-specific cellular assays:

  • Immunofluorescence microscopy to visualize subcellular localization changes upon phosphorylation

  • Flow cytometry with phospho-specific antibodies for single-cell analysis

  • Proximity ligation assays to detect protein-protein interactions dependent on phosphorylation status

• Kinase/phosphatase manipulation:

  • Employ specific inhibitors of IκB kinases (IKKs) to block phosphorylation

  • Use phosphatase inhibitors to maintain phosphorylation

  • Implement genetic approaches using kinase/phosphatase knockdown or dominant-negative constructs

• Mass spectrometry approaches:

  • Quantitative phosphoproteomics to identify multiple phosphorylation sites

  • SILAC or TMT labeling for quantitative comparison across conditions

  • Phospho-enrichment techniques to enhance detection of low-abundance phosphopeptides

These approaches should ideally be combined to provide comprehensive understanding of the dynamic regulation of NFKBIE phosphorylation in cellular signaling contexts.

How can researchers differentiate between the functions of phosphorylated NFKBIE and other phosphorylated IκB proteins?

Distinguishing the specific functions of phosphorylated NFKBIE from other IκB family members requires strategic experimental approaches:

• Genetic manipulation with isoform specificity:

  • Generate NFKBIE-specific knockout or knockdown models

  • Create phospho-mimetic (S22D/E) and phospho-deficient (S22A) NFKBIE mutants

  • Perform rescue experiments with wild-type or mutant constructs in knockout backgrounds

• Temporal resolution studies:

  • Compare kinetics of phosphorylation among different IκB proteins following stimulus

  • Identify stimulus-specific patterns (e.g., TNF-α vs. IL-1β) that might preferentially target NFKBIE

  • Use cycloheximide chase experiments to compare degradation kinetics

• Interactome analyses:

  • Conduct co-immunoprecipitation with phospho-specific antibodies to identify unique binding partners

  • Perform BioID or proximity labeling to identify proteins near phosphorylated NFKBIE

  • Compare interaction maps between different phosphorylated IκB proteins

• Target gene specificity:

  • Conduct ChIP-seq after specific knockdown of NFKBIE to identify uniquely regulated NF-κB target genes

  • Perform RNA-seq following selective manipulation of NFKBIE phosphorylation

  • Compare gene expression patterns regulated specifically by NFKBIE versus other IκB proteins

• Structural studies:

  • Examine whether phosphorylation induces unique conformational changes in NFKBIE compared to other IκB proteins

  • Compare binding affinities to specific NF-κB subunits when phosphorylated

Research indicates that NFKBIE has distinct interactions with specific NF-κB family members including RELA, RELB, REL, and NFKB1, suggesting functional specificity that can be further explored through these methods .

How might NFKBIE function as a therapeutic target in cancer and inflammatory diseases?

Emerging research suggests several strategic approaches for targeting NFKBIE in therapeutic contexts:

• Small molecule modulators:

  • Develop compounds that either prevent NFKBIE phosphorylation or stabilize the phosphorylated form

  • Target the interaction between phosphorylated NFKBIE and ubiquitin ligase machinery

  • Design molecules that selectively disrupt NFKBIE-NF-κB interactions while preserving other IκB functions

• Immunotherapeutic approaches:

  • Exploit NFKBIE's differential expression in various immune cell populations

  • Target NFKBIE in combination with immune checkpoint inhibitors

  • Develop strategies based on NFKBIE's positive correlation with B-cell immune infiltration in tumors

• Pathway-specific interventions:

  • Target NFKBIE in combination with PI3K/AKT pathway inhibitors, given their demonstrated interaction

  • Explore synergistic effects with RAS/MAPK pathway modulators

  • Consider dual targeting of NFKBIE and mTOR pathways

• Biomarker development:

  • Utilize phospho-NFKBIE (S22) as a predictive biomarker for treatment response

  • Develop companion diagnostics using phospho-specific antibodies

  • Stratify patients based on NFKBIE expression/phosphorylation status

Research indicates that NFKBIE knockdown significantly decreases both proliferation and migration of HCC cells, suggesting direct therapeutic potential for targeted inhibition . Additional studies have identified potential associations between NFKBIE and drug sensitivity, with low expression correlating with resistance to specific compounds like Z-LLNle-Cho and dabrafenib .

What experimental approaches can resolve contradictory findings about NFKBIE function in different disease contexts?

To address conflicting findings regarding NFKBIE function across different disease contexts, researchers should consider these methodological approaches:

• Context-dependent studies:

  • Compare NFKBIE function across multiple cell types derived from the same tissue

  • Examine NFKBIE regulation in primary cells versus established cell lines

  • Investigate tissue-specific knockout models to reveal context-dependent phenotypes

• Integration of multi-omics data:

  • Correlate phospho-proteomics, transcriptomics, and interactomics data

  • Use systems biology approaches to model context-specific networks

  • Apply machine learning to identify patterns in large datasets that might explain contradictory findings

• Technical standardization:

  • Develop consensus protocols for phospho-NFKBIE detection and quantification

  • Create reference standards for antibody validation

  • Establish reporting guidelines for experimental conditions that might influence outcomes

• Microenvironmental considerations:

  • Evaluate NFKBIE function in co-culture systems mimicking tissue environments

  • Assess impact of hypoxia, pH, and nutrient availability on NFKBIE regulation

  • Examine extracellular matrix components that might modulate NF-κB pathway behavior

• Temporal dynamics analysis:

  • Compare acute versus chronic activation models

  • Assess feedback loops that might reverse initial signaling events

  • Implement live-cell imaging with fluorescent reporters to track real-time dynamics

Research has revealed that NFKBIE expression significantly correlates with certain clinical characteristics, including tumor grade, P53 mutation status, and tumor stage, suggesting that contradictory findings might be explained by heterogeneity in these features across studies .